Evidence map›Paper›PMID 26000097›Full record

ArticleGenes & cancer2015

Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma.

Blake A Jacobson, Esther Z Chen, Shaogeng Tang, Holly Sedgwick Belgum, Joel A McCauley, Kristen A Evenson, Ryan G Etchison, Joe Jay-Dixon, Manish R Patel, Ahmad Raza and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Heat Shock Proteins in Lymphoma Immunotherapy.Frontiers in immunology · 2021
    Review
  14. Article
  15. Review
  16. Mutant p53Cancer letters · 2019
    Article
  17. Frontiers in pharmacology · 2019
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Blake A JacobsonDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Esther Z ChenDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Shaogeng TangDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Holly Sedgwick BelgumDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Joel A McCauleyDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Kristen A EvensonDepartments of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Ryan G EtchisonDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Joe Jay-DixonDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Manish R PatelDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Ahmad RazaDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Ashok K SalujaDepartments of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Jonathan D'CunhaDepartments of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Robert A KratzkeDepartments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma is a devastating disease with a poor prognosis for which there is a clear need for more successful therapeutic approaches. Triptolide, a diterpenoid triepoxide, is a highly effective agent against several cancer types in animal models. Owing to triptolide's poor solubility in water, a water-soluble analog, minnelide, was synthesized. Minnelide is a prodrug of triptolide and is activated by exposure to phosphatases that are found in all body tissues, including blood. Mesothelioma cells were treated in vitro with minnelide or its parent compound, triptolide. Minnelide and triptolide were both found to significantly reduce mesothelioma cell viability and induce apoptosis. The level of Hsp70, a protein that promotes cancer cell survival, was measured in mesothelioma cells before and after treatment with triptolide. Hsp70 levels were decreased in a dose-dependent manner. In addition, triptolide sensitized cells to gemcitabine and pemetrexed as measured by cell viability. Mice bearing mesothelioma flank tumors were treated with daily injections (28 d) of minnelide or saline solution and xenograft tumor growth recorded. Mice displayed significantly reduced tumor burden. These findings support the clinical evaluation of minnelide therapy for mesothelioma.

Indexed as

Hsp70mesotheliomaminnelideTriptolide

Identifiers

PMID26000097
PMCPMC4426951
OpenAlexW239014235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.